PMCB (PharmaCyte Biotech) Shares Outstanding (Basic Average) : 7.87 Mil (As of Jul. 2024)

PharmaCyte Biotech Shares Outstanding (Basic Average) Chart

PharmaCyte Biotech Annual Data
	Trend	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
Shares Outstanding (Basic Average)		Get a 7-Day Free Trial					0.90	1.45	15.52	19.49	9.58

PharmaCyte Biotech Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Shares Outstanding (Basic Average)	Get a 7-Day Free Trial															12.60	8.77	8.61	8.35	7.87

PharmaCyte Biotech Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

PharmaCyte Biotech  (NAS:PMCB) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

PharmaCyte Biotech Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description